Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 22;44(6):126.
doi: 10.1007/s10875-024-01734-5.

Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity

Affiliations

Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity

Satoshi Miyamoto et al. J Clin Immunol. .

Abstract

Alemtuzumab is used with reduced-toxicity conditioning (RTC) in allogeneic hematopoietic cell transplantation (HCT), demonstrating efficacy and feasibility for patients with inborn errors of immunity (IEI) in Western countries; however, the clinical experience in Asian patients with IEI is limited. We retrospectively analyzed patients with IEI who underwent the first allogeneic HCT with alemtuzumab combined with RTC regimens in Japan. A total of 19 patients were included and followed up for a median of 18 months. The donors were haploidentical parents (n = 10), matched siblings (n = 2), and unrelated bone marrow donors (n = 7). Most patients received RTC regimens containing fludarabine and busulfan and were treated with 0.8 mg/kg alemtuzumab with intermediate timing. Eighteen patients survived and achieved stable engraftment, and no grade 3-4 acute graft-versus-host disease was observed. Viral infections were observed in 11 patients (58%) and 6 of them presented symptomatic. The median CD4+ T cell count was low at 6 months (241/µL) but improved at 1 year (577/µL) after HCT. Whole blood cells continued to exhibit > 80% donor type in most cases; however, 3/10 patients exhibited poor donor chimerism only among T cells and also showed undetectable levels of T-cell receptor recombination excision circles (TRECs) at 1 year post-HCT. This study demonstrated the efficacy and safety of alemtuzumab; however, patients frequently developed viral infections and slow reconstitution or low donor chimerism in T cells, emphasizing the importance of monitoring viral status and T-cell-specific chimerism. (238 < 250 words).

Keywords: Alemtuzumab; Asian; Hematopoietic cell transplantation; Inborn errors of immunity; Retrospective study.

PubMed Disclaimer

Similar articles

References

    1. Guilcher GMT, Shah R, Shenoy S. Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: a review. Pediatr Transpl. 2018;22(2).
    1. Tomizawa D, Miyamura T, Imamura T, Watanabe T, Saito AM, Ogawa A, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813–23. - DOI - PubMed
    1. Kawaguchi K, Umeda K, Miyamoto S, Yoshida N, Yabe H, Koike T, et al. Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders. Bone Marrow Transpl. 2023;58(5):600–2. - DOI
    1. Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. [Internet]. Bone Marrow Transplantation; 2013 p. 452–8. (Bone Marrow Transplantation). http://www.nature.com/articles/bmt2012244 .
    1. Takashima T, Okamura M, Yeh T, wen, Okano T, Yamashita M, Tanaka K, et al. Multicolor Flow Cytometry for the diagnosis of primary Immunodeficiency diseases. J Clin Immunol. 2017;37(5):486–95. - DOI - PubMed

Publication types

Supplementary concepts

Grants and funding

LinkOut - more resources